Tag: lung cancer

1. Osimertinib demonstrated a significantly longer duration of progression-free survival compared to standard of care epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in patients with untreated EGFR-mutated locally-advanced or metastatic non-small-cell lung cancer (NSCLC). 2. Osimertinib treated patients had fewer grade 3 or higher adverse events compared to patients...

First-line nivolumab in stage IV or recurrent non-small-cell lung cancer Platinum-based combination chemotherapy has long been used in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC). However, chemotherapy only provides moderate benefit, with median progression-free survival and overall survival limited to 4-6 months and 10-13 months, respectively....

1. In a retrospective review of over 17 000 patients in the National Lung Screening Trial (NLST), there was a high prevalence of potentially significant extra-pulmonary findings. 2. The incidence of extrapulmonary malignancy detected in NLST was low. Evidence Rating Level: 3 (Average) Study Rundown: The NLST was a large randomized controlled...

1. In this clinical demonstration project of implementing lung cancer screening for smokers in selected Veterans Health Administration hospitals, there were challenges in project implementation and patient selection. There was significant variability in local implementation and radiographic detection of nodules. 2. Increasing the scale of lung cancer screening to the...

Treatment with Ledipasvir-Sofosbuvir for 12 or 24 weeks in Kidney Transplant Recipients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial Previous data has shown that interferon and ribavirin use in the treatment of chronic hepatitis C virus (HCV) infection in kidney transplant recipients is limited...

1. Progression free survival and overall survival was significantly increased in patients who received pembrolizumab vs. patients who received platinum-based chemotherapy. 2. Treatment related toxicities were nearly doubled in the chemotherapy group vs. the pembrolizumab group. Evidence Rating Level: 1 (Excellent)  Study Rundown: Pembrolizumab is a humanized monoclonal antibody against programmed death...

1. ND-646, a small molecule inhibitor of FASyn, an enzyme involved in fatty acid synthesis, caused reduced growth and viability of non-small cell lung cancer (NSCLC) cells in vitro. 2. In two mouse models of NSCLC, ND-646 curbed tumor growth when given as a single agent and in combination with the...

  Safety of Seasonal Influenza Vaccination in Hospitalized Surgical Patients: A Cohort Study There are concerns about the potential side effects of influenza vaccinations that develop in the perioperative period, specifically the development of vaccine-associated fever or myalgia. It is thought that these symptoms may be incorrectly attributed to an infectious...

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer Although docetaxel is currently used, effective second line chemotherapy agents are limited for patients with non-small cell lung cancer (NSCLC). This study was a randomized, open label, phase 3 clinical trial involving 582 patients with stage IIIB, IV or recurrent NSCLC...

1. In a retrospective review of over 190 patients with primary lung cancers, patients with lower grade emphysema and airway-predominant disease as determined by pulmonary computed tomography had a significantly higher frequency of central lung cancers as compared to patients with severe emphysema. Evidence Rating Level: 3 (Average)        Study Rundown: Chronic...